Stock Ratings / Health Care / PLUR / insiders

SCLX (52) JSPR (41) DYAI (33) BCDA (49) ⌘ Pro Terminal →

Pluri Inc. (PLUR) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.20 -2.44% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Pluri Inc. (PLUR) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $16.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PLUR)Realized 20D OHLCV Swing Band: ±12.5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

PLUR Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (PLUR)

No recent open-market Form 4 cluster sales or emergency dumps flagged on PLUR. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PLUR)

✓Walkthrough of PLUR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PLUR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -65.52%⚡ TESTING RESISTANCE

2026-10-30O $1.31H $1.31L $1.20C $1.20VOL 29.3K

RES: $1.41SUP: $0.65SMA50: $1.16SMA200: $2.38

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PLUR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PLUR Butterfly Map → + Track PLUR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PLUR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PLUR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PLUR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PLUR)

Health Care Rank #683 of 1016 ⚔️ SCLX vs PLUR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PLUR vs. SCLX, JSPR, DYAI, BCDA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Pluri Inc. (PLUR) ranks #683 by composite RQD confidence (39/100, grade D-) and #852 by equity capitalization ($16.1M). Within this direct 5-issuer industry benchmark cohort, PLUR leads on earnings valuation at N/A trailing P/E, while PLUR leads on capital efficiency and profitability with -35.0% ROIC and 49.0% gross margin. SCLX currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with PLUR at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PLUR ACTIVE Pluri Inc.	D-	39/100	—	49.0%	-35.0%	-2.44%	$16.1M	Benchmark Subject
SCLX Scilex Holding Company	D+	52/100	—	96.0%	-35.0%	-1.43%	$17.5M	/sclx-vs-plur →
JSPR Jasper Therapeutics Inc.	D-	41/100	—	—	-35.0%	-1.26%	$17.7M	/jspr-vs-plur →
DYAI Dyadic International Inc.	E	33/100	—	24.9%	-35.0%	-8.40%	$14.5M	/dyai-vs-plur →
BCDA BioCardia Inc.	D	49/100	—	—	-35.0%	-2.26%	$14.0M	/bcda-vs-plur →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001158780

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Pluri Inc. (PLUR) reported GAAP revenue of $1.3M (+309.8% vs. FY2024 revenue of $326.0K , and +365.5% cumulative change since FY2023) , GAAP net income of -$22.6M, operating cash flow of -$18.2M, and free cash flow of -$19.8M (-8.1% YoY). On the balance sheet, PLUR closed FY2025 with $30.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$1.3M	-$22.6M	-$18.2M	-$19.8M	$30.6M	—
FY2024 (FY)	2024-06-30	$326.0K	$21.3M	-$18.0M	-$18.3M	$30.9M	—
FY2023 (FY)	2023-06-30	$287.0K	$28.9M	-$22.9M	-$22.9M	—	—

3. PLUR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PLUR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Pluri Inc. (NASDAQ: PLUR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.20 (-2.44% 1D, market cap $16.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PLUR ranks #683 in composite RQD confidence.

How does PLUR compare to SCLX and JSPR in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PLUR carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of 49.0%, and ROIC of -35.0%. By comparison, SCLX (Scilex Holding Company) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -35.0%, cap $17.5M) and JSPR (Jasper Therapeutics Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $17.7M). Among the 5-stock peer group, PLUR leads on earnings multiple (N/A) while PLUR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PLUR?

Per PLUR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001158780), Pluri Inc. generated $1.3M in revenue (+309.8% YoY), -$22.6M in net income, and -$19.8M in free cash flow against $30.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PLUR trading relative to its 50-day, 200-day, and 52-week technical levels?

PLUR last traded at $1.20 (-2.44% on volume of 38,527 shares), positioning the stock +3.45% above its 50-day simple moving average ($1.16) and -49.58% below its 200-day simple moving average ($2.38). Across its 52-week range of $0.85 to $4.87, PLUR sits at the 8.7% percentile with a 14-day RSI of 61.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.05 to $1.35).

PLUR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are PLUR insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies PLUR leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: PLUR RQD Cockpit PLUR 12M Forecast PLUR Earnings & Move PLUR Dividends & DRIP PLUR Insiders & 13F PLUR Whale Options PLUR Profit Sankey PLUR News & Why